CR Intrinsic Investors’s Pfizer PFE Stock Holding History

CR Intrinsic Investors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-158,100	Closed	-$4.82M	–	129
2014 Q1	$4.82M	Buy	+158,100	New	+$4.71M	0.18%	175
2013 Q3	–	Sell	-3,997	Closed	-$106K	–	388
2013 Q2	$106K	Buy	+3,997	New	+$110K	﹤0.01%	326

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

CR Intrinsic Investors's PFE Position: Q2 2014 in Review

CR Intrinsic Investors sold out of Pfizer (PFE) in Q2 2014, closing a stake of 158,100 shares — an estimated $4.82M sold.

CR Intrinsic Investors first reported a position in PFE in Q2 2013 and held it in 2 quarters. The position peaked at $4.82M in Q1 2014. 1,747 funds tracked by Wall St. Rank hold PFE as of Q2 2014.

CR Intrinsic Investors reported no remaining Pfizer position as of Q2 2014 after selling out during the quarter.
CR Intrinsic Investors sold 158,100 Pfizer shares in Q2 2014, an estimated $4.82M.
CR Intrinsic Investors first reported a position in Pfizer in Q2 2013 and held it in 2 quarters.
CR Intrinsic Investors's Pfizer position peaked at $4.82M in Q1 2014.
1,747 funds tracked by Wall St. Rank held Pfizer as of Q2 2014.

Based on CR Intrinsic Investors's 13F filing for Q2 2014.